Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

C4 Therapeutics (CCCC) Income from Continuing Operations (2019 - 2025)

C4 Therapeutics' Income from Continuing Operations history spans 7 years, with the latest figure at 20365000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 41.1% year-over-year to 20365000.0; the TTM value through Dec 2025 reached 104873000.0, changed 0.42%, while the annual FY2025 figure was 104994000.0, 0.31% changed from the prior year.
  • Income from Continuing Operations reached 20365000.0 in Q4 2025 per CCCC's latest filing, up from 32166000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 15658000.0 in Q4 2021 to a low of 37185000.0 in Q4 2022.
  • Average Income from Continuing Operations over 5 years is 27710900.0, with a median of 26957500.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: plummeted 137.48% in 2022, then skyrocketed 50.68% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 15658000.0 in 2021, then tumbled by 137.48% to 37185000.0 in 2022, then rose by 6.53% to 34757000.0 in 2023, then rose by 0.53% to 34573000.0 in 2024, then skyrocketed by 41.1% to 20365000.0 in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Income from Continuing Operations are 20365000.0 (Q4 2025), 32166000.0 (Q3 2025), and 26020000.0 (Q2 2025).